文献速递肝病

间歇性禁食——NASH患者的未来治疗?

Intermittent fasting-the future treatment in NASH patients?
PubMed 文献 · Hepatology · 2023-04-17

本文综述了间歇性禁食作为NASH潜在治疗手段的临床证据。基础和临床研究显示,间歇性禁食除减轻体重、改善血压、胆固醇、甘油三酯、胰岛素和葡萄糖代谢等心脏代谢参数外,还可降低炎症标志物、内质网应激、氧化应激、自噬和内皮功能障碍,并调节肠道菌群。本综述旨在探讨间歇性禁食可作用的NASH主要致病代谢驱动因素并总结当前临床证据。

要点

  • 间歇性禁食可减轻体重并改善血压、胆固醇、甘油三酯、胰岛素和葡萄糖代谢等心脏代谢参数。
  • 间歇性禁食可降低炎症标志物、内质网应激、氧化应激、自噬和内皮功能障碍,并调节肠道菌群。
  • 本综述旨在探讨间歇性禁食可作用的NASH主要致病代谢驱动因素并总结当前临床证据。

核心结论

  • 间歇性禁食可能作用于NASH的多个致病代谢驱动因素,从而改善疾病预后,但需进一步研究。

研究设计与样本

  • 本文为综述,旨在探讨间歇性禁食可作用的NASH主要致病代谢驱动因素并总结当前临床证据。

主要发现

  • 基础和临床研究显示,间歇性禁食除诱导体重减轻外,还可改善血压、胆固醇和甘油三酯水平、胰岛素和葡萄糖代谢等心脏代谢参数。
  • 间歇性禁食可降低炎症标志物、内质网应激、氧化应激、自噬和内皮功能障碍,并调节肠道菌群。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

NASH is one of the leading causes of chronic liver disease with the potential of evolving towards end-stage liver disease and HCC, even in the absence of cirrhosis. Apart from becoming an increasingly prevalent indication for liver transplantation in cirrhotic and HCC patients, its burden on the healthcare system is also exerted by the increased number of noncirrhotic NASH patients. Intermittent fasting has recently gained more interest in the scientific community as a possible treatment approach for different components of metabolic syndrome. Basic science and clinical studies have shown that apart from inducing body weight loss, improving cardiometabolic parameters, namely blood pressure, cholesterol, and triglyceride levels; insulin and glucose metabolism; intermittent fasting can reduce inflammatory markers, endoplasmic reticulum stress, oxidative stress, autophagy, and endothelial dysfunction, as well as modulate gut microbiota. This review aims to further explore the main NASH pathogenetic metabolic drivers on which intermittent fasting can act upon and improve the prognosis of the disease, and summarize the current clinical evidence.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Minciuna I, Gallage S, Heikenwalder M, et al. Intermittent fasting-the future treatment in NASH patients? Hepatology. 2023. PMID: 37057877. doi:10.1097/HEP.0000000000000330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。